Effects of low-dose recombinant human insulin-like growth factor-I on insulin sensitivity, growth hormone and glucagon levels in young adults with insulin-dependent diabetes mellitus

Metabolism: Clinical and Experimental

Volumn 47, Issue 12, 1998, Pages 1481-1489

  Acerini, C L ^b   Harris, D A ^b   Matyka, K A ^b   Watts, A P ^b   Umpleby, A M ^b   Russell Jones, D L ^b   Dunger, D B ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT SOMATOMEDIN C;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; GLUCAGON BLOOD LEVEL; GROWTH HORMONE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031647461     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(98)90074-9     Document Type: Article

References (60)

1. Kuzuya H, Matsuura N, Sakamoto M, et al: Trial of insulin like growth factor I therapy for patients with extreme insulin resistance syndromes. Diabetes 42:696-705, 1993
2. Moses AC, Morrow LA, O'Brien M, et al: Insulin-like growth factor I (rhIGF-I) as a therapeutic agent for hyperinsulinaemic insulin-resistant diabetes mellitus. Diabetes Res Clin Pract 28:S185-S194, 1995 (suppl)
3. Schoenle EJ, Zenobi PD, Torresani T, et al: Recombinant human insulin-like growth factor I (rhIGF-I) reduces hyperglycaemia in patients with extreme insulin resistance. Diabetologia 34:675-679, 1991
4. Schalch DS, Turman NJ, Marcsisin VS, et al: Short-term effects of recombinant human insulin-like growth factor I on metabolic control of patients with type II diabetes mellitus. J Clin Endocrinol Metab 77:1563-1568, 1993
5. Zenobi PD, Glatz Y, Keller A, et al: Beneficial metabolic effects of insulin-like growth factor I in patients with severe insulin-resistant diabetes type A. Eur J Endocrinol 131:251-257, 1994
6. Moses AC, Young SC, Morrow LA, et al: Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycaemic control in type II diabetes. Diabetes 45:91-100, 1996
7. RhIGF-I in NIDDM Study (RINDS) Group: Evidence from a dose ranging study that recombinant insulin-like growth factor I (rhIGF-I) effectively and safely improves glyacemic control in noninsulin dependent diabetes mellitus (NIDDM). Diabetes 45:27A, 1996 (suppl 2, abstr)
8. Cheetham TD, Jones J, Taylor AM, et al: The effects of recombinant insulin-like growth factor I administration on growth hormone levels and insulin requirements in adolescents with type 1 (insulin dependent) diabetes mellitus. Diabetologia 36:678-681, 1993
9. Bach MA, Chin E, Bondy CA: The effects of subcutaneous insulin-like growth factor-I infusion in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 79:1040-1045, 1994
10. Cheetham TD, Holly JMP, Clayton K, et al: The effects of repeated daily recombinant human insulin-like growth factor I administration in adolescents with type I diabetes. Diabet Med 12:885-892, 1995
11. Quattrin T, Thrailkill K, Baker L, et al: Dual hormonal replacement with insulin and recombinant human insulin-like growth factor I in IDDM. Effects on glycemic control, IGF-I levels, and safety profile. Diabetes Care 20:374-380, 1997
12. Amiel SA, Sherwin RS, Hintz RL, et al: Effect of diabetes and its control on insulin like growth factors in the young subject with type I diabetes. Diabetes 33:1175-1179, 1984
13. Taylor AM, Dunger DB, Grant DB, et al: Somatomedin-C/IGF-I measured by immunoassay and somatomedin bioactivity in adolescents with insulin dependent diabetes compared with puberty matched controls. Diabetes Res 9:177-181, 1988
14. Batch JA, Baxter RC, Werther G: Abnormal regulation of insulin-like growth factor binding proteins in adolescents with insulin dependent diabetes. J Clin Endocrinol Metab 73:964-968, 1991
15. Edge JA, Dunger DB, Matthews DR, et al: Increased overnight growth hormone concentrations in diabetics compared with normal adolescents. J Clin Endocrinol Metab 71:1356-1362, 1990
16. McGuire EAH, Helderman JH, Tobin JD, et al: Effects of arterial versus venous sampling on analysis of glucose kinetics in man. J Appl Physiol 41:565-573, 1976
17. Collins ACG, Pickup JC: Sample preparation and radioimmunoassay for circulating free and antibody bound insulin concentrations in insulin treated diabetics: A re-evaluation of methods. Diabet Med 2:456-460, 1985
18. Mellanby J, Williamson DH: Acetoacetate, in Bergmeyer HV (ed): Methods of Enzymatic Analysis, vol 4. New York, NY, Academic, 1974, pp 1840-1843
19. Williamson DH, Mellanby J: D-(-)-3-Hydroxybutyrate, in Bergmeyer HV (ed): Methods of Enzymatic Analysis, vol 4. New York, NY, Academic, 1974, pp 1836-1839
20. Weicko J, Sherman WR: Boroacetylation of carbohydrates. Correlations between structure and mass spectral behaviour in monoacetylhexose cyclic boronic esters. J Am Chem Soc 98:7631-7637, 1976
21. DeBodo RC, Steele R, Altszuler N, et al: On the hormonal regulation of carbohydrate metabolism: Studies with C14 glucose. Recent Prog Horm Res 19:445-482, 1963
22. Finegood DT, Bergman RN, Vranic M: Estimation of endogenous glucose production during hyperinsulinaemic-euglycaemic glucose clamps. Diabetes 36:914-924, 1987
23. 2H2] glucose enriched glucose infusion during hyperinsulinaemic euglycaemic clamps. Eur J Clin Invest 22:244-253, 1992
24. Wilton P, Sietnieks A, Gunnarsson R, et al: Pharmacokinetic profile of recombinant human insulin-like growth factor I given subcutaneously in normal subjects. Acta Paediatr Scand Suppl 377:111-114, 1991
25. Guler H-P, Schmid C, Zapf J, et al: Effects of recombinant insulin-like growth factor I on insulin secretion and renal function in normal human subjects. Proc Natl Acad Sci USA 86:2868-2872, 1989
26. Rennert NJ, Caprio S, Sherwin RS: Insulin-like growth factor I inhibits glucose-stimulated insulin secretion but does not impair glucose metabolism in normal humans. J Clin Endocrinol Metab 76:804-806, 1993
27. Atiea JA, Creagh F, Page M, et al: Early morning hyperglycemia in insulin dependent diabetes: Acute and sustained effects of cholinergic blockade. J Clin Endocrinol Metab 69:390-395, 1989
28. Cheetham TD, Clayton KL, Taylor AM, et al: The effects of recombinant human insulin-like growth factor I on growth hormone secretion in adolescents with insulin dependent diabetes mellitus. Clin Endocrinol (Oxf)40:515-522, 1994
29. Dunger DB, Cheetham TD, Crowne EC: Insulin-like growth factors (IGFs) and IGF-I treatment in the adolescent with insulin-dependent diabetes mellitus. Metabolism 44:119-123, 1995 (suppl 4)
30. Berlowitz M, Szabo M, Frohman LA, et al: Somatomedin-C mediates growth hormone negative feedback by effects on both the hypothalamus and the pituitary. Science 212:1279-1281, 1981
31. Yamashita S, Melmed S: Insulin like growth factor-I regulation of growth hormone gene transcription in primary rat pituitary cells. J Clin Invest 79:449-452, 1987
32. Ceda GP, Davis RG, Rosenfeld RG, et al: The growth hormone (GH)-releasing hormone (GHRH)-GH somatomedin axis: Evidence of rapid inhibition of GHRH elevated GH release by insulin-like growth factors I and II. Endocrinology 120:1658-1662, 1987
33. Rizza RA, Mandarine LJ, Gerich JE: Effects of growth hormone on insulin action in man. Mechanisms of insulin resistance, impaired suppression of glucose production, and impaired stimulation of glucose utilization. Diabetes 31:663-669, 1982
34. Bratusch-Marrain PR, Smith D, DeFronzo RA: The effect of growth hormone on glucose metabolism and insulin secretion in man. J Clin Endocrinol Metab 55:973-982, 1982
35. Fowelin J, Attvall S, von Schenck H, et al: Characterization of the insulin-antagonistic effect of growth hormone in man. Diabetologia 34:500-506, 1991
36. Pal BR, Phillips PE, Matthews DR, et al: Contrasting metabolic effects of continuous and pulsatile growth hormone administration in young adults with type 1 (insulin dependent) diabetes mellitus. Diabetologia 35:542-549, 1992
37. Beaufrére B, Beylot M, Metz G, et al: Dawn phenomenon in type I (insulin dependent) diabetic adolescents: Influence of nocturnal growth hormone secretion. Diabetologia 31:607-611, 1988
38. Perriello G, DeFeo P, Torlone E, et al: Nocturnal spikes of growth hormone secretion cause the dawn phenomenon in type I (insulin dependent) diabetes mellitus by decreasing hepatic (and extrahepatic) sensitivity to insulin in the absence of insulin waning. Diabetologia 33:52-59, 1990
39. Edge JA, Matthews DR, Dunger DB: The dawn phenomenon is related to overnight growth hormone release in adolescent diabetics. Clin Endocrinol (Oxf) 33:729-737, 1990
40. Cheetham TD, Connors M, Clayton K, et al: Insulin sensitivity before and after recombinant human insulin-like growth factor I (rhIGF-I) administration in adolescents with IDDM: Importance of GH concentrations. Clin Endocrinol (Oxf) 46:415-425, 1997
41. Hussain MA, Schmitz O, Mengel A, et al: Insulin-like growth factor I stimulates lipid oxidation, reduces protein oxidation and enhances insulin sensitivity in humans. J Clin Invest 92:2249-2256, 1993
42. Sindelar DK, Balcom JH, Chu CA, et al: A comparison of the effects of selective increases in peripheral or portal insulin on hepatic glucose production in the conscious dog. Diabetes 45:1594-1604, 1996
43. Sherwin RS, Hendler R, DeFronzo R, et al: Glucose homeostasis during prolonged suppression of glucagon and insulin secretion by somatostatin. Proc Natl Acad Sci USA 74:348-352, 1977
44. Boulware SD, Tamborlane WV, Rennert NJ, et al: Comparison of the metabolic effects of recombinant human insulin-like growth factor-I and insulin. Dose-response relationships in healthy young and middle aged adults. J Clin Invest 93:1131-1139, 1994
45. Crowne EC, Samra JS, Cheetham T, et al: Recombinant human insulin-like growth factor-I abolishes changes in insulin requirements consequent upon growth hormone pulsatility in young adults with type I diabetes mellitus. Metabolism 47:31-38, 1998
46. Caro JF, Poulos J, Ittoop O, et al: Insulin-like growth factor I binding in hepatocytes from human liver, human hepatoma, and normal, regenerating, and fetal rat liver. J Clin Invest 81:976-981, 1988
47. Zapf J, Schoenle E, Waldvogel M, et al: Effect of trypsin treatment of rat adipocytes on biological effects and binding of insulin and insulin-like growth factors: Further evidence for the action of insulin-like growth factors through the insulin receptor. Eur J Biochem 113:605-609, 1981
48. Moxley RT, Arner P, Moss A, et al: Acute effects of insulin-like growth factor I and insulin on glucose metabolism in vivo. Am J Physiol 259:E561-E567, 1990 (suppl)
49. Giacca A, Gupta R, Efendic S, et al: Differential effects of IGF-I and insulin on glucoregulation and fat metabolism in depancreatised dogs. Diabetes 39:340-347, 1990
50. Jacob R, Barrett E, Plewe G, et al: Acute effects of insulin-like growth factor I on glucose and amino acid metabolism in the awake fasted rat. J Clin Invest 83:1717-1723, 1989
51. Turkalj I, Keller U, Ninnis R, et al: Effect of increasing doses of recombinant human insulin-like growth factor-I on glucose, lipid and leucine metabolism in man. J Clin Endocrinol Metab 75:1186-1191, 1992
52. Boulware SD, Tamborlane WV, Matthews LS, et al: Diverse effects of insulin-like growth factor I on glucose, lipid, and amino acid metabolism. Am J Physiol 262:E130-E133, 1992 (suppl)
53. Russell-Jones DL, Bates AT, Umpleby AM, et al: A comparison of the effects of IGF-I and insulin on glucose metabolism, fat metabolism and the cardiovascular system in normal human volunteers. Eur J Clin Invest 25:403-411, 1995
54. Elahi D, McAloon-Dyke M, Fukagawa NK, et al: Effects of recombinant human IGF-I on glucose and leucine kinetics in men. Am J Physiol 265:E831-E838, 1993 (suppl)
55. Lewitt MS, Denyer GS, Cooney GJ, et al: Insulin-like growth factor binding protein-1 modulates blood glucose levels. Endocrinology 129:2254-2256, 1991
56. Cheetham TD, Taylor A, Holly JMP, et al: The effects of recombinant human insulin-like growth factor-I (IGF-I) administration on the levels of IGF-I, IGF-II and IGF-binding proteins in adolescents with insulin-dependent diabetes mellitus. J Endocrinol 142:367-374, 1994
57. Baxter RC, Hizuka N, Takano K, et al: Responses of insulin-like growth factor binding protein-1 (IGFBP-1) and the IGFBP-3 complex to administration of insulin-like growth factor-I. Acta Endocrinol (Copenh) 128:101-108, 1993
58. Holly JMP, Biddlecombe RA, Dunger DB, et al: Circadian variation of GH-independent IGF-binding protein in diabetes mellitus and its relationship to insulin. A new role for insulin? Clin Endocrinol (Oxf) 29:667-675, 1988
59. Edge JA, Pal BR, Harris DA, et al: Evidence for a role for insulin and growth hormone in the overnight regulation of 3-hydroxybutyrate in normal and diabetic adolescents. Diabetes Care 16:1011-1018, 1993
60. Bolinder J, Lindbald A, Engfeldt P, et al: Studies of acute effects of insulin-like growth factors I and II in human fat cells. J Clin Endocrinol Metab 65:732-737, 1987